Corpus Intelligence IC Memo — LAKE TAYLOR TRANSITIONAL CARE HOSPIT 2026-04-26 06:25 UTC
IC Memo — LAKE TAYLOR TRANSITIONAL CARE HOSPIT
Investment Committee Memorandum | VA | 104 beds | Grade C | EBITDA uplift $3.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LAKE TAYLOR TRANSITIONAL CARE HOSPIT

CCN 492001 | NORFOLK, VA | 104 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LAKE TAYLOR TRANSITIONAL CARE HOSPIT is a 104-bed safety-net/medicaid heavy in NORFOLK, VA with $51.4M in net patient revenue and a 14.6% operating margin. The hospital serves a payer mix of 1.8% Medicare, 85.5% Medicaid, and 12.7% commercial.

Thesis: Turnaround. Our ML models identify $3.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 14.6% to 21.9% (+736bps).

Net Revenue HCRIS$51.4M
Current EBITDA COMPUTED$7.5M
Operating Margin COMPUTED14.6%
Occupancy HCRIS54.6%
Revenue / Bed COMPUTED$495K
Net-to-Gross HCRIS74.6%
Distress Probability ML70.9%

2. Market Context & Competitive Position

111
VA Hospitals
4.4%
State Median Margin
53
Comparable Hospitals

VA has 111 Medicare-certified hospitals with a median operating margin of 4.4%. The target's margin of 14.6% places it above the state median. Among 53 size-comparable peers (52-208 beds), the median margin is 5.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (52-208), prioritizing same-state peers. 53 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LAKE TAYLOR TRANSITIONAL CARE (Target)VA104$51.4M14.6%
CHILDRENS HOSPITAL OF THE KINGVA202$546.2M-9.9%
INOVA LOUDOUN HOSPITAL CENTERVA189$510.3M22.9%
RESTON HOSPITALVA201$385.5M34.6%
INOVA FAIR OAKS HOSPITALVA174$382.5M28.5%
SENTARA MARTHA JEFFERSON HOSPIVA150$362.0M-6.4%
SENTARA PRINCESS ANNE HOSPITALVA174$361.5M10.3%
MARYVIEW HOSPITALVA160$348.0M-2.5%
ST. FRANCIS MEDICAL CENTERVA128$339.6M8.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.1M+210bp18mo
Cost to Collect4.5%2.5%$1.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$626K+122bp9mo
Clean Claim Rate88.0%96.0%$33K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.1M
Cost to Collect
$1.0M
Denial Rate Reduction
$1.0M
A/R Days Reduction
$626K
Clean Claim Rate
$33K
Total EBITDA Uplift$3.8M
Current EBITDA$7.5M
+ RCM Uplift+$3.8M
Pro Forma EBITDA$11.3M
Current Margin14.6%
Pro Forma Margin21.9%
WC Released (1x)$2.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$11.5M$87.3M7.57x49.9%
Base (11x exit)10.0x11.0x$11.5M$99.8M8.65x54.0%
Bull Case9.0x11.0x$10.4M$116.0M11.18x62.1%
Bull (12x exit)9.0x12.0x$10.4M$129.6M12.49x65.7%
Bear Case11.0x10.0x$12.7M$64.6M5.10x38.5%
Bear (11x exit)11.0x11.0x$12.7M$75.2M5.93x42.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (85.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 70.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 53 hospitals with 52-208 beds
  • Same-state prioritization (n=54)
  • Comp margins: P25=-7.4% / P50=5.7% / P75=17.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.